MacroGenics and Merck study margetuximab/pembrolizumab combination
MacroGenics Inc. and Merck & Co. Inc. entered into a trial collaboration to conduct Phase Ib/II studies on a combination therapy involving MacroGenics' monoclonal antibody margetuximab together with Merck's Keytruda (pembrolizumab) for advanced gastric cancer.
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com